WORST OF CALLABLE BARRIER REVERSE CONVERTIBLE NOTE - NOVAVAX/ROCHE GS Stock

Certificat

GS0221

GB00BP8GP870

Market Closed - Borsa Italiana 11:44:59 2024-05-09 am EDT
10.62 EUR 0.00% Intraday chart for WORST OF CALLABLE BARRIER REVERSE CONVERTIBLE NOTE - NOVAVAX/ROCHE GS
Current month+1.43%
1 month-3.45%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change Volume
24-05-09 10.62 0.00% 7
24-05-08 10.62 0.00% 15
24-05-07 10.62 -2.75% 19
24-05-06 10.92 +1.87% 19
24-05-03 10.72 0.00% 16

Real-time Borsa Italiana

Last update May 09, 2024 at 11:44 am EDT

More quotes

Static data

Product typeReverse Convertibles
Buy / SellCALL
Underlying ROCHE HOLDING AG
Issuer Goldman Sachs
GS0221
ISINGB00BP8GP870
Date issued 2022-01-11
Strike 375.6 CHF
Maturity 2025-01-06 (242 Days)
Parity 1 : 1
Emission price 100
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 96.85
Lowest since issue 9.75
Spread 1.75
Spread %15.22%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
222.3 CHF
Average target price
279.4 CHF
Spread / Average Target
+25.68%
Consensus
  1. Stock Market
  2. Certificates
  3. GS0221 Certificat
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW